

Subject Index to Volume 3 (1986)

- absorbtion, 108
acetylcholine, 162
acylglycosyloxy alkaloids, 240
additivity rules, 65
amaryllidaceae, 240
aminodarone, 167
8-aminoquinoline, 170
analgesic testing, 263
anticholinergics, 327
antihemophilic factors, 364
antipyrine, 156
antiviral nucleoside, 112
Aspergillus ochraceus, 170
Athreosclerosis, 52
- betamethasone, 244
binary powder mixtures, 65
bioassay, 302
bioavailability, 108, 253
blood brain barrier, 81, 278
bradykinin, 162
brain microvessel endothelium, 81
- calf brain, 327
cancer chemotherapy, 311
capping, 65
carbopol, 214
carboxyprimaquine, 132
Crinum asiaticum, 240
catalepsy, 162
cefixime, 150
cellulose water interactions, 187
cephalosporin, 150
chemilumescence, 271
cholesterol, 93
cholesterol lowering agents, 286
codeine, 45
compact hardness tests, 12
compactibility, 12, 65
compressibility, 12, 65
compression, 65
compression equations, 12
conjugate synthesis, 132
controlled drug delivery, 318
cyclosporin A, 48
cytochrome P-450, 156
cytotoxicity, 302
- DHPG, 112
dibromoculcitol, 302
diffusion, 21
diethylcarbomazine, 75
dimensions, 356
dissolution, 88
diuretics, potassium-sparing, 102
dogs, 123
dopamine, 7, 162
drug absorbtion, 123
drug carrier, 35
drug delivery, 23, 81, 225, 244, 318, 333
drug interaction, 167
drug metabolizing enzyme activity, 156
dynamic light scattering, 214
- electroosmosis, 318
endorphins, 56
endorphins, 142
endothelium, 81
enhanced rectal absorbtion, 116
enkephalins, 162
ethyl cellulose, 230
excised skin, 356
- fieldscreening, 132
filariasis, 75
floating formulations, 208
fluorescent dyes, 56
fusogenic lipid, 116
- gas chromatography, 298
gastric emptying, 208
Gastrointestinal
 drug absorbtion, 123
 mobility and pH, 123
 tract, 123
 transit, 123
gels, 21
gel formation, 230
glucose-6-phosphate dehydrogenase, 290
glucuronide, 132
glycine conjugate, 132
- heterogeneity, 327
hexyl nicotinate, 294
high performance liquid chromatography, of peptides, 142
homophthalimide, 286
human epidermis, 61
hydrophilic compounds, 345
hypolipidemic agents, 286
hypolipidemic activity, 93
- immunostimulant, 307
immunosuppressive activity, 48
induction, 156
inhibition, 156
intranasal, 108
interferon suppository, 116
intestine, 345
intestinal absorbtion, 35
iontophoresis, 318
in vivo methods, 263
- leukotriene B4, 271
lipid, 23
liposome, 23
long acting drugs, 56
lycoriside, 240
lymphotropic delivery, 116
- mast cells, 240
malaria, 290
malnutrition, 352
mangiferin, 307
MAO, 7

- measurement of codeine in plasma, 45
 mefruside, 41
 membrane, 23
 membrane filter sterility test, 364
 metabolism, 352, 170
 metabolic clearance corrections, 150
 methylprimaquine, 170
 metronidazole, 352
 microbial growth inhibition, 364
 microviscosity, 214
 molecular biology, 195
 molecular modeling, 311
 monolayers, 81
 morphians, 218
 morphology, 356
 muscarinic receptors, 327
 mucosal membrane permeability, 345
 multilayered vesicle, 23
 multiple dose, 179
- naloxone, 263
 narcotic antagonists, 56
 narcotics, 56
 nasal solutions, 298
 neurotoxins, 7
 nitroglycerine, 61
 nonhydrolyzable cholesteryl ester probe, 52
 nonpiperazine compounds, 75
 nonprotein thiol, 345
 norethindrone, 278
 nucleic acids, 311
 nucleic acid conformation, 311
- ocular effects,
 oleic acid, 35
 oligonucleotides, 195
 opiate receptor, 218
 opioids, 263
- Parkinson's disease, 7
 pellet density, 208
 penetration enhancers, 294
 peptide region specific radioimmunoassay, 142
 percutaneous absorption, 294, 253
 permeation through skin, 61
 pharmacokinetics, 108
 pharmacology, cutaneous, 253
 piperazines, 75
 polyamines, 311
 polyethylene glycol, 230
 polymer-water interactions, 187
 polymorphonucleargranulocyte, 271
 polyvinylpyrrolidone, 41
 powder, 88
 powder compression, 12
 preparation, 356
 primary culture, 81
 primaquine metabolism, 290
 prodrugs, 333
 progestins, 278
 promotive absorption, 35
 propanolol, 108
 prostaglandins, 162
- pyrrol derivatives, 271
 pyrrolopyrimidines, 271
- quaternary ammonium derivatives, 298
- rabbit, 52
 radiochemical degradation, 360
 radioiodinated cholesteryl iopanoate, 52
 radiolabeled degradation products, 360
 rats, 156, 352
 receptors, 56
 receptor interaction, 327
 recombinant DNA, 195
 renal clearance, 150
 reversible metabolism, 173, 178
 RIA, 112
- saturable protein binding, 150
 serotonin, 162
 single dose, 173
 skin permeation, rats and dogs, 225
 soft gelatin capsules, 230
 solid dispersions, 41
 starch-water interactions, 187
 sterility testing, 364
 sticking, 65
 strength of a compact, 65
 sublingual, 108
 sulfamerazine suspensions, 118
 sulfapyrazone, 173, 178
 surface active ingredients, 298
 suspensions, xanthum gum, 118
 sustained delivery of drugs, 278
 sustained release, 230
- theophylline, 156, 167
 therapeutic proteins, 364
 thermal decomposition, 298
 thermal stability, 41
 thonzonium bromide, 298
 timolol, 225
 tolnaftate, 88
 topical, 88
 topical drugs, bioavailability, 233
 transdermal drug delivery, 318
 triamterene, 102
 triglyceride lowering agents, 286
 tritium decay, 360
 tubular reabsorption, 150
- ufasome, 35
 urea, 294
- variability with age, 61
- water-excipient interactions, 187
 water-polymer interactions, 187
 water vapor sorption, 187
- xanthum gum suspensions, 118
 xanthene-C-glucoside, 307